CA-NEXTIVITY
15.3.2022 07:02:04 CET | Business Wire | Press release
Nextivity today announced that Nordic distributor Tura Scandinavia AB has the first European installation of Cel-Fi QUATRA 4000e underway. The new multi-carrier hybrid active DAS (distributed antenna system) for the EMEA market has been deployed at Elgiganten and Rusta stores in northern Stockholm, Sweden so customers and employees can now use their cell phones anywhere inside the stores, and experience good quality reception.
Spotty cellular coverage, poor voice quality, dropped calls, and dead zones continue to impact employees and customers in many retail buildings. Cel-Fi QUATRA 4000e is an affordable, all-digital, multi-carrier active DAS hybrid solution that solves this issue by providing uniform, high quality cellular signal throughout any commercial building. This industry-leading system is also carrier approved and guaranteed network safe.
“There was no cellular reception at all inside the Elgiganten and Rusta stores due to the metal construction of the buildings, which is common for commercial property in Sweden,” says Terje Skatterod, Senior Technology Officer at Tura Scandinavia, a Nordic distributor that offers mobile, data, and cellular equipment for retailers through a network of system integrators. “Cel-Fi QUATRA has improved the signal inside the stores by 25 dBM, which is equivalent to increasing the coverage by almost 100 times.”
“As Cel-Fi QUATRA is 5G-ready, building owners get a greater return on their investment with this modern solution which is upgradable,” explains Sverre Platou, Nextivity Brand Manager at Tura Scandinavia. “The system is also all-digital, using ethernet rather than coax cabling, which makes installation easier and reduces the installation cost to about a quarter of traditional repeater systems.”
“Cel-Fi QUATRA is starting to get a lot of attention in the Nordic region. Unlike other equipment, you don't need the RF skills to install it. You can simply use a local electrician to run the cabling and hook it up to the internet, and one telecom RF engineer to deploy the whole solution remotely,” Skatterod says.
Tura Scandinavia, which was named best European distributor in 2021 by Nextivity, has several installations of the new Cel-Fi QUATRA 4000e scheduled for other retailers in Sweden and throughout Europe. For more information about QUATRA, visit cel-fi.com/buy .
“Tura Scandinavia is a strong strategic partner for Nextivity, bringing our best-in-class cellular coverage solutions to the reseller community,” says David Cabanes, Nextivity Vice-President of European Sales. “With product offerings now available for enterprise, small and mid-size businesses, mobile, and micro solutions, we look forward to continuing to work with Tura Scandinavia to help their partners expand their capabilities and market reach.”
About Tura Scandinavia AB
Tura Scandinavia AB is a leading Nordic distributor of accessories in Audio, Video, Mobile, Data, Photography, TV, Gaming and SDA. Our philosophy is: a wide range, strong brands and fast delivery. The business was founded in Gothenburg in 1976 and we currently operate in Sweden, Denmark, Finland and Norway. The head office is located in Kungsbacka and the logistics center in Nässjö, Sweden.
About Nextivity
Headquartered in San Diego, Nextivity Inc. develops the award-winning, Cel-Fi family of products that deliver best-in-class connectivity for enterprise, business, residential spaces, and mobile cellular and public safety communication needs. Cel-Fi is the go-to solution for healthcare, government, hotels, retail, education, remote sites, parking garages, manufacturing, warehouses, as well as trucking and marine fleets. Cel-Fi products are available in 100 countries through mobile operators and a growing worldwide network of master distributors, systems integrators, installers, and resellers. Additional information is available at cel-fi.com , on Twitter , LinkedIn , and on Facebook .
Nextivity, the Nextivity logo, Cel-Fi, Smart Signal Booster, and Supercell are registered trademarks of Nextivity Incorporated in the United States and/or other countries. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005864/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
